What is Enable Injections?
Cincinnati-based Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of the enFuse On-Body Delivery System. This innovative wearable technology is engineered to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration. By prioritizing patient convenience and superior clinical outcomes, the company is actively advancing healthcare system economics. Enable Injections operates at the intersection of medical device engineering and biopharmaceutical delivery, providing a critical solution for patients requiring complex, high-volume medication regimens outside of clinical settings.
How much funding has Enable Injections raised?
Enable Injections has raised a total of $309M across 7 funding rounds:
Private Equity
$2M
Multiple Rounds
$60M
Debt
$2M
Series C
$215M
Other Financing Round
$30M
Private Equity (2012): $2M, investors not publicly disclosed
Private Equity (2016): $5M, investors not publicly disclosed
Private Equity (2016): $25M, investors not publicly disclosed
Series A (2016): $30M featuring CincyTech, Cintrifuse, and Cincinnati Childrenu2019s Hospital Medical Center
Debt (2020): $2M backed by PPP
Series C (2022): $215M with participation from GCM Grosvenor, Magnetar Capital, and Squarepoint Capital
Other Financing Round (2026): $30M led by Sanofi
Key Investors in Enable Injections
Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation, focusing on immunology, rare diseases, and oncology.
GCM Grosvenor
GCM Grosvenor is a global alternative asset management solutions provider that invests in private equity, infrastructure, and diverse growth equity opportunities.
Magnetar Capital
Magnetar Capital is a financial investment firm specializing in hedge fund strategies and collateralized debt obligations within global markets.
What's next for Enable Injections?
With the recent strategic investment, Enable Injections is poised to transition into a new phase of commercial expansion and operational maturity. The focus will likely shift toward scaling the production of the enFuse system to meet increasing demand from global pharmaceutical partners. Furthermore, the company is expected to deepen its integration into the biopharmaceutical supply chain, leveraging its unique delivery technology to enhance the efficacy and accessibility of next-generation biologic therapies. As the firm continues to navigate the complexities of the healthcare market, its strategic roadmap will prioritize regulatory milestones, manufacturing excellence, and the broadening of its therapeutic application portfolio to address diverse patient needs.
See full Enable Injections company page
